Glaukos Corporation is a glaucoma treatment company based in Laguna Hills, California. Thomas Burns is Glaukos' president and CEO. Glaukos developed the "iStent" titanium micro-stent. The device, which is about the width of a human hair, is implanted during cataract surgery to reduce intraocular pressure. As of 2015[update], the iStent was the smallest device ever approved by the United States Food and Drug Administration. The availability of the iStent led to the addition of two codes to the Current Procedural Terminology set in 2015, 0191T and 0376T. In 2015, Glaukos planned to transition from private company status to become a public company with an initial public offering (IPO) of company stock. The proposed stock symbol for the company was "GKOS".